Overview
Tesamorelin (brand name Egrifta) is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH) specifically indicated for the treatment of excess abdominal fat (lipodystrophy) in HIV-infected patients. It's the only FDA-approved peptide for reducing visceral adipose tissue.
As a GHRH analog, tesamorelin stimulates the pituitary gland to produce and release growth hormone, which helps reduce visceral fat accumulation while maintaining subcutaneous fat distribution. This makes it particularly valuable for addressing metabolic complications associated with HIV treatment.
How It Works
- GHRH receptor activation: Stimulates natural growth hormone release
- Visceral fat reduction: Specifically targets abdominal fat deposits
- Metabolic enhancement: Improves insulin sensitivity and glucose metabolism
- IGF-1 elevation: Increases growth factor levels for tissue health
Benefits
- Visceral fat reduction: Clinically proven reduction in abdominal fat
- Improved body composition: Better fat distribution patterns
- Metabolic benefits: Enhanced insulin sensitivity
- Quality of life: Improved self-image and confidence
- Cardiovascular health: Reduced visceral adiposity benefits
Protocol & Dosing
- Standard dose: 2 mg daily subcutaneously
- Administration: Evening injection into abdomen
- Treatment duration: Typically 6+ months for optimal results